Omeros (NASDAQ:OMER) Raised to Hold at Wall Street Zen

Omeros (NASDAQ:OMER) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Other analysts have also issued research reports about the stock. D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Tuesday, January 27th. HC Wainwright raised their price objective on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $40.33.

Omeros Stock Performance

Shares of Omeros stock opened at $10.90 on Friday. The stock has a market capitalization of $784.80 million, a PE ratio of -21.80 and a beta of 2.53. Omeros has a 52 week low of $2.95 and a 52 week high of $17.65. The stock has a 50 day moving average price of $11.36 and a two-hundred day moving average price of $9.91.

Omeros (NASDAQ:OMER) last issued its earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.55) by $3.69. Research analysts forecast that Omeros will post -3.09 EPS for the current year.

Insider Activity

In related news, CAO David J. Borges sold 30,000 shares of Omeros stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 12.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Omeros

Large investors have recently bought and sold shares of the stock. Corient Private Wealth LLC boosted its holdings in Omeros by 13.0% during the 4th quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company’s stock worth $11,817,000 after acquiring an additional 79,263 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Omeros in the fourth quarter valued at about $159,000. Invesco Ltd. lifted its position in shares of Omeros by 26.8% during the fourth quarter. Invesco Ltd. now owns 154,782 shares of the biopharmaceutical company’s stock valued at $2,658,000 after purchasing an additional 32,707 shares in the last quarter. Virtus Investment Advisers LLC purchased a new position in Omeros during the fourth quarter worth about $450,000. Finally, Wellington Management Group LLP boosted its holdings in Omeros by 4.2% during the fourth quarter. Wellington Management Group LLP now owns 202,617 shares of the biopharmaceutical company’s stock worth $3,480,000 after purchasing an additional 8,170 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

Omeros News Summary

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Omeros says it has reached a profitability milestone as part of a strategic shift toward commercialization and partnerships, which management says should improve cash flow and de-risk the business. Omeros Reaches Profitability Milestone Amid Strategic Shift
• Positive Sentiment: HC Wainwright raised near-term EPS estimates for multiple 2026 quarters and lifted FY2026/FY2027 forecasts, while keeping a Buy rating and a $40 price target — a bullish analyst stance that supports higher share valuations. HC Wainwright raises estimates and reiterates Buy, $40 PT
• Positive Sentiment: Q4 results were stronger than expected (company-reported EPS beat and a licensing/deal with Novo Nordisk cited as boosting Q4), providing immediate revenue/earnings proof points that likely pushed the stock higher. Omeros rises as Novo deal boosts Q4 earnings
• Positive Sentiment: Unusually large call-option purchases were reported, signaling bullish positioning by traders and adding short-term upside pressure. Traders Purchase Large Volume of Call Options on Omeros
• Neutral Sentiment: Several analyst and market-commentary pieces outline the bull case ahead of Q1 commercial updates and provide earnings-call detail — useful for context but not immediate catalysts on their own. Omeros: Making The Bull Case On Q4 Earnings
• Neutral Sentiment: Earnings call transcript and summaries are available for deeper detail on guidance and commercialization plans; these will matter when management discusses Q1 commercial progress. Q4 2025 Earnings Call Transcript
• Negative Sentiment: HC Wainwright trimmed several longer-term EPS estimates (FY2028–FY2030), lowering some multi-year upside expectations — a signal that while near-term outlook improved, longer-term model risk remains. HC Wainwright trims long-term EPS forecasts

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.